InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2024 Financial Report, Corporate Update
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting its financial results for the first quarter of 2024, the period ending June 30, 2023; the company also released a corporate update. Highlights of the report include positive top-line results from the company’s phase 3…